{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "adults receiving remifentanil-based anesthesia"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing intravenous magnesium vs. placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "We aimed to assess whether intravenous magnesium reduces postoperative pain, analgesic requirements, and hyperalgesia in adults receiving remifentanil-based anesthesia."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Primary outcomes were postoperative analgesic requirements and pain scores"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Twenty-two RCTs ( n = 1362) met eligibility."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Magnesium significantly decreased 24 h analgesic requirements (standardized mean difference [SMD] \u22121.51; 95% confidence interval [CI] \u22122.15 to \u22120.87; p < 0.0001) and pain scores (SMD \u22120.61; 95% CI \u22120.90 to \u22120.32; p < 0.0001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "without prolonging extubation or increasing hypotension/bradycardia risk"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "PROSPERO registration: CRD42024609911"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}